Citation Impact
Citing Papers
Zygomycetes in Human Disease
2000 Standout
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
2010 Standout
Epidemiology of Invasive Mycoses in North America
2010
Early Versus Delayed Antiretroviral Therapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis
2013 StandoutNobel
Toxoplasmosis snapshots: Global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis
2009 Standout
Primary Cutaneous Cryptococcosis: A Distinct Clinical Entity
2003
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Natural products: A continuing source of novel drug leads
2013 Standout
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
2017 Standout
Pulmonary Cryptococcosis in the Immunocompetent Host
2000
Antifungal Agents. Part II. The Azoles
1999
Phylogenetic Species Recognition and Species Concepts in Fungi
2000 Standout
Prevalence, Determinants of Positivity, and Clinical Utility of Cryptococcal Antigenemia in Cambodian HIV-Infected Patients
2007
Immunocompromised Hosts: Cryptococcosis in Solid Organ Transplant Recipients: Current State of the Science
2008
Soft-Tissue Sarcomas in Adults
2005 Standout
Physical Maps for Genome Analysis of Serotype A and D Strains of the Fungal Pathogen Cryptococcus neoformans
2002
Cryptococcus neoformansInfection in Organ Transplant Recipients: Variables Influencing Clinical Characteristics and Outcome
2001
Cryptococcosis in Organ Transplant Recipients: An Overview
2002
Candida albicanspathogenicity mechanisms
2013 Standout
Pulmonary Cryptococcosis in Nonimmunocompromised Patients
2003
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans
2008 StandoutNobel
Current Options in Antifungal Pharmacotherapy
2008
Cryptococcosis
2006
Major Role for Amphotericin B–Flucytosine Combination in Severe Cryptococcosis
2008
Glucocorticoids and invasive fungal infections
2003
Cryptococcus gattii:in vitrosusceptibility to the new antifungal albaconazole versus fluconazole and voriconazole
2005
The Changing Epidemiology of Cryptococcosis: An Update from Population‐Based Active Surveillance in 2 Large Metropolitan Areas, 1992–2000
2003
Horizontal gene transfer in eukaryotic evolution
2008 Standout
Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy
2006
Epidemiology and Host- and Variety-Dependent Characteristics of Infection Due to Cryptococcus neoformans in Australia and New Zealand
2000
Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development
1998
Recent Evolution of the Human Pathogen Cryptococcus neoformans by Intervarietal Transfer of a 14-Gene Fragment
2006
Spleen deposition ofCryptococcus neoformanscapsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1
2008 StandoutNobel
In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs
2006
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS
2009 Standout
Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France
2005
Cryptococcal Meningitis in a Neonate
2002
Cryptococcosis in Human Immunodeficiency Virus–Negative Patients in the Era of Effective Azole Therapy
2001
Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence
2006
Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa
2013
Cryptococcal glucuronoxylomannan interferes with neutrophil rolling on the endothelium
2004
Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study
2007
Cryptococcosis and Idiopathic CD4 Lymphocytopenia
2007
Practice Guidelines for the Management of Cryptococcal Disease
2000 Standout
The Poor Prognosis of Central Nervous System Cryptococcosis among Nonimmunosuppressed Patients: A Call for Better Disease Recognition and Evaluation of Adjuncts to Antifungal Therapy
2006
Cas1p is a membrane protein necessary for the O‐acetylation of the Cryptococcus neoformans capsular polysaccharide
2001
Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy
2000
Effect of Immune Mechanisms on the Pharmacokinetics and Organ Distribution of Cryptococcal Polysaccharide
1998
Cryptococcosis
2002
Antifungal agents: mechanisms of action
2003 Standout
Role of laccase in the biology and virulence of
2004
Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas
2004
An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
2010
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Survey of European programmes for the epidemiological surveillance of congenital toxoplasmosis
2008
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
2016 Standout
Zygomycetes in Human Disease
2000 Standout
Cryptococcus neoformans var. grubii : Separate Varietal Status for Cryptococcus neoformans Serotype A Isolates
1999
Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance
1999 Standout
Current and Emerging Azole Antifungal Agents
1999 Standout
Hemicelluloses
2010 Standout
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
2005 Standout
Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis
2006
Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi
2015 Standout
Cryptococcus neoformansInfection in Organ Transplant Recipients: Variables Influencing Clinical Characteristics and Outcome
2001
Immunogenicity and Efficacy ofCryptococcus neoformansCapsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice
2003
Guidelines for Treatment of Candidiasis
2004 Standout
Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease
2008
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans
1995 Standout
Galleria mellonella as a Model System To Study Cryptococcus neoformans Pathogenesis
2005 Standout
Works of S. Mathoulin being referenced
Standards, Options and Recommendations (SOR) for diagnosis, treatment and follow-up of osteosarcoma
1999
Dépistage et détection précoce en transfusion sanguine : quand sont-ils indiqués ?
1997
Individual and Environmental Factors Associated with Infection Due to Cryptococcus neoformans Serotype D
1996
Comparison of the Efficacy of Amphotericin B and Fluconazole in the Treatment of Cryptococcosis in Human Immunodeficiency Virus-Negative Patients: Retrospective Analysis of 83 Cases
1996
Epidemiology of Cryptococcosis in France: A 9-Year Survey (1985-1993)
1996
[Standards, options and recommendations (SOR) for diagnosis, treatment and follow-up of osteosarcoma. Groupe de travail SOR].
1999
Molecular typing of Cryptococcus neoformans serotype D clinical isolates
1994